Deep brain stimulation (DBS) currently comprises only about a quarter of the worldwide neuromodulation device market, but growth in this segment is strong. Both large and small competitors have targeted DBS, which has the potential to address a number of highly prevalent and underserved diseases and disorders.

The cardiac interventional suite has historically welcomed high-tech, cutting-edge tools. But with hospitals scrutinizing expenditures more closely than ever before, such tools must now prove themselves. Hospitals are now placing a premium on technologies that can improve safety, efficiency, and flexibility while streamlining workflow. A handful of companies are now offering products designed to meet these needs, and providers are starting to take notice.

Indoco’s domestic performance picks up pace as the Indian pharma market sees a “bounce back” after a long COVID-induced slump.  The Indian company continues to perform well internationally and grow overall.